Newsfile Corp
24 Jun 2026, 19:45 UTC · 18w ago
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Impact · against what's priced in
ADMA Biologics faces significant valuation risks following a class action lawsuit alleging revenue manipulation via channel stuffing and failures in internal controls. While other companies listed (VIA, Z, SRAD) are also facing legal challenges, the ADMA allegations regarding fraud and related-party transactions are particularly severe.
- ADMA−0.70
No priced-in read yet





